PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23169295-10 2012 In validation study, ERCC1 and DPD but not TOP1 expressions in cancer cells were significantly higher in FOLFOX (oxaliplatin, folinic acid, and 5-FU)-treated patients (N=24) than nontreated patients (N=21). Leucovorin 126-138 dihydropyrimidine dehydrogenase Homo sapiens 31-34 17097873-0 2007 Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. Leucovorin 125-135 dihydropyrimidine dehydrogenase Homo sapiens 10-41 17097873-6 2007 Patients with a high-normal DPD activity proved to be at risk of developing mild toxicity upon treatment with 5FU-leucovorin, suggesting an important role of DPD in the aetiology of toxicity associated with catabolites of 5FU. Leucovorin 114-124 dihydropyrimidine dehydrogenase Homo sapiens 28-31 17097873-6 2007 Patients with a high-normal DPD activity proved to be at risk of developing mild toxicity upon treatment with 5FU-leucovorin, suggesting an important role of DPD in the aetiology of toxicity associated with catabolites of 5FU. Leucovorin 114-124 dihydropyrimidine dehydrogenase Homo sapiens 158-161 12006517-1 2002 PURPOSE: This study determined the effect of different weekly dosing schedules of 5-fluorouracil (5-FU)/leucovorin (LV)/eniluracil on dihydropyrimidine dehydrogenase (DPD) activity and plasma uracil levels. Leucovorin 104-114 dihydropyrimidine dehydrogenase Homo sapiens 134-165 15222105-0 2004 [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer]. Leucovorin 88-98 dihydropyrimidine dehydrogenase Homo sapiens 9-40 15025795-0 2004 Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. Leucovorin 113-123 dihydropyrimidine dehydrogenase Homo sapiens 0-31 12006517-0 2002 Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition. Leucovorin 78-88 dihydropyrimidine dehydrogenase Homo sapiens 108-139 12006517-1 2002 PURPOSE: This study determined the effect of different weekly dosing schedules of 5-fluorouracil (5-FU)/leucovorin (LV)/eniluracil on dihydropyrimidine dehydrogenase (DPD) activity and plasma uracil levels. Leucovorin 104-114 dihydropyrimidine dehydrogenase Homo sapiens 167-170 12006517-1 2002 PURPOSE: This study determined the effect of different weekly dosing schedules of 5-fluorouracil (5-FU)/leucovorin (LV)/eniluracil on dihydropyrimidine dehydrogenase (DPD) activity and plasma uracil levels. Leucovorin 116-118 dihydropyrimidine dehydrogenase Homo sapiens 134-165 12006517-1 2002 PURPOSE: This study determined the effect of different weekly dosing schedules of 5-fluorouracil (5-FU)/leucovorin (LV)/eniluracil on dihydropyrimidine dehydrogenase (DPD) activity and plasma uracil levels. Leucovorin 116-118 dihydropyrimidine dehydrogenase Homo sapiens 167-170 9264323-0 1997 Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor. Leucovorin 53-65 dihydropyrimidine dehydrogenase Homo sapiens 73-104 11459999-3 2001 Two patients treated in a phase I trial of oral 5-FU, leucovorin and eniluracil, an inhibitor of dihydropyrimidine dehydrogenase (DPD), developed delayed onset symptoms of unsteady gait and reduced sensation in the legs. Leucovorin 54-64 dihydropyrimidine dehydrogenase Homo sapiens 97-128 11459999-3 2001 Two patients treated in a phase I trial of oral 5-FU, leucovorin and eniluracil, an inhibitor of dihydropyrimidine dehydrogenase (DPD), developed delayed onset symptoms of unsteady gait and reduced sensation in the legs. Leucovorin 54-64 dihydropyrimidine dehydrogenase Homo sapiens 130-133 10778957-5 2000 DPD expressions were measured by quantitative reverse transcription-PCR in 33 pretreatment biopsies of colorectal tumors from patients who went on to receive treatment with 5-FU and leucovorin (LV). Leucovorin 182-192 dihydropyrimidine dehydrogenase Homo sapiens 0-3 10778957-5 2000 DPD expressions were measured by quantitative reverse transcription-PCR in 33 pretreatment biopsies of colorectal tumors from patients who went on to receive treatment with 5-FU and leucovorin (LV). Leucovorin 194-196 dihydropyrimidine dehydrogenase Homo sapiens 0-3 11977552-2 2002 We report a patient with metachronous liver metastasis from rectal cancer with low expression of DPD, who demonstrated complete response to chemotherapy comprising 5-FU, Leucovorin, and UFT. Leucovorin 170-180 dihydropyrimidine dehydrogenase Homo sapiens 97-100 11241325-4 2001 UFT (uracil:tegafur) plus oral leucovorin (Orzel) is the first oral DPD-inhibitory fluoropyrimidine. Leucovorin 31-41 dihydropyrimidine dehydrogenase Homo sapiens 68-71 11081569-4 2000 Two oral fluoropyrimidines commonly referred to as DPD inhibitory fluoropyrimidines, or DIFs, UFT plus leucovorin (LV) and S-1 are reviewed herein. Leucovorin 103-113 dihydropyrimidine dehydrogenase Homo sapiens 51-54 11081569-4 2000 Two oral fluoropyrimidines commonly referred to as DPD inhibitory fluoropyrimidines, or DIFs, UFT plus leucovorin (LV) and S-1 are reviewed herein. Leucovorin 115-117 dihydropyrimidine dehydrogenase Homo sapiens 51-54 10874920-5 2000 Promising new agents: 5-FU prodrugs and inhibitors of dihydropyrimidine dehydrogenase (DPD) are promising chemotherapeutic agents with good oral bioavailability which can be combined with other drugs (leucoverin) with acceptable toxicity. Leucovorin 201-211 dihydropyrimidine dehydrogenase Homo sapiens 54-85 10874920-5 2000 Promising new agents: 5-FU prodrugs and inhibitors of dihydropyrimidine dehydrogenase (DPD) are promising chemotherapeutic agents with good oral bioavailability which can be combined with other drugs (leucoverin) with acceptable toxicity. Leucovorin 201-211 dihydropyrimidine dehydrogenase Homo sapiens 87-90